Project Grant HT94252310160
Award Date
4/1/23
Completion Date
3/31/24
Dollars Obligated
$165K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Los Angeles, CA 90089, USA
Similar Awards
The University of Southern California (USC) was awarded a $915,936 Project Grant from the U.S. Department of Defense's Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The funding supports research to investigate SETD2 deficiency as a therapeutic target to upregulate viral mimicry for treating aggressive clear cell renal cell carcinoma in patients. This award is part of the program's focus on cancer, neurological disorders, and other health...
This $1,113,749 Project Grant awarded by the Defense Health Agency (CFDA 12.420 - Military Medical Research and Development) to the University of Southern California (USC) supports the development of Synthetic Immune Receptor T (SIR-T) cells targeting the B7-H3 protein for the treatment of renal cancer. The grant, which commenced on September 15, 2023, will fund a 3-year research project to explore this novel immunotherapeutic approach for addressing renal cancer. As a leading private research...
The University of Southern California (USC) received a $1,992,000 Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program. The award, effective September 15, 2025 through September 14, 2028, is for the development of a "Synthetic Immune Receptor for the Treatment of Prostate Cancer". The Military Medical Research and Development program supports advanced biomedical research aimed at transforming...
The University of Southern California will receive $413,750 through September 2025 under a Project Grant from the Defense Health Agency to develop next-generation chimeric antigen receptor T cells targeting folate receptor 1 for the treatment of ovarian cancer. Funded through the Military Medical Research and Development program (CFDA 12.420), this award will support the grantee's applied medical research efforts to investigate innovative solutions for battlefield health care and transform...
This Project Grant award was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to the University of Texas Southwestern Medical Center. The $1,312,000 grant, with a period of performance from July 1, 2024 to June 30, 2028, will support research on biomarkers and mechanisms of acquired resistance to immunotherapy for renal cell carcinoma. This work aims to improve understanding and treatment of this form of kidney cancer, which is a...
The University of Southern California (USC) Department of Contracts and Grants Division was awarded a $331,630 Project Grant by the Defense Health Agency under the "Military Medical Research and Development" (CFDA 12.420) program. The grant supports research into mRNA delivery for polycystic kidney disease, with a period of performance from November 15, 2023 to November 14, 2025. As a leading private research university, USC leverages its expertise in engineering, health sciences,...
This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $999,096.00 to The University of Texas Southwestern Medical Center to conduct research on "Targeting DNA Damage Response to Treat Clear Cell Renal Cell Carcinoma." The award period runs from July 1, 2024 to June 30, 2028. The research aims to develop new treatments for clear cell renal cell carcinoma, a type of kidney cancer, by investigating...
The Johns Hopkins University will receive $334,652 under a three-year Project Grant award from the Defense Health Agency to characterize the prognostic and predictive role of immune cell population changes induced by neoadjuvant PD-1 inhibition in clear cell renal cell carcinoma. The grant is funded through the Military Medical Research and Development program (CFDA 12.420), which supports biomedical research to transform military and public health care through innovative solutions for...
This federal Project Grant award of $1,185,996.00 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) will support research by the Medical University of South Carolina (MUSC) to "EXPLOIT IMMUNE SIGNATURES FROM IMMUNOTHERAPY RESPONSE IN METASTATIC RENAL CELL CANCER TO IMPROVE QUALITY OF LIFE AND SURVIVAL OF VETERANS." The award period runs from September 1, 2025 to August 31, 2028. The Military Medical Research and Development program...
This Project Grant award, valued at $708,750.00, was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The funding supports the development of a next-generation, off-the-shelf CAR-NKT cell therapy for the treatment of metastatic clear cell renal cell carcinoma. The award was granted to the University of California, Los Angeles (UCLA) on September 15, 2024, with a performance period ending on September 14, 2026. UCLA, as the prime...